Estradiol+MPA — Competitive Intelligence Brief

Estradiol+MPA (Estradiol+MPA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT). Area: Endocrinology / Women's Health.

marketed Hormone replacement therapy (HRT) Estrogen receptor alpha and beta; progesterone receptor Endocrinology / Women's Health Small molecule

Target snapshot

Estradiol+MPA (Estradiol+MPA) — Brigham and Women's Hospital. Estradiol and medroxyprogesterone acetate (MPA) together provide hormone replacement therapy by supplementing estrogen and progestin to alleviate menopausal symptoms and reduce bone loss.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estradiol+MPA TARGET	Estradiol+MPA	Brigham and Women's Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
Estradiol/norethindrone acetate	Estradiol/norethindrone acetate	Myovant Sciences GmbH	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
Transdermal estrogen	Transdermal estrogen	University of Utah	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estrogen therapy	estrogen therapy	Beni-Suef University	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
EVOREL® CONTI	EVOREL® CONTI	Royal Brompton & Harefield NHS Foundation Trust	marketed	Hormone replacement therapy (HRT) — combined estrogen/progestin	Estrogen receptors (ER-α, ER-β) and progesterone receptor (PR)
Estradiol + Medroxy Progesterone Acetate	Estradiol + Medroxy Progesterone Acetate	Erasmus Medical Center	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Femoston® 1, Femoston® 2	Femoston® 1, Femoston® 2	Scientific Research Institute of Public Health, Russian Federation	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) class)

1. Anna Posadzy-Małaczyńska · 1 drug in this class
2. Beni-Suef University · 1 drug in this class
3. Brigham and Women's Hospital · 1 drug in this class
4. El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
5. Erasmus Medical Center · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. Myovant Sciences GmbH · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. Scientific Research Institute of Public Health, Russian Federation · 1 drug in this class
10. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class